- Developed a preclinical research platform for screening, optimizing and validating lead compounds with targeted activity against an aggressive form of B-cell lymphoma.- Led a team of 4 medicinal chemists, molecular biologists, and computational biologists in IND-enabling studies on a novel class of NFkB inhibitors as anti-tumor agents.

- Generated & presented company creation strategies based on cutting edge science.- Validated venture hypotheses by interviewing KOLs from academic, medical and business backgrounds.

- Managed, pre-screened and recruited incoming deal flow for the angel investment group. - Performed due diligence on prospective investment opportunities. - Co-managed 1st Pitch Life Science – Quarterly event that enables start-up companies to pitch to local investors. Has grown 3x (Philadelphia, NJ, NYC) & acquired sponsors (~$50,000/yr).

- Developed initial value story for target customer market (home health agencies), based on quantification of system cost reductions and productivity increases. - Performed market research to identify best suited target market for product launch.

- Created sustainable revenue strategy for a prospective biotech incubator in NY that helped secure a Small Business Association grant and sponsorships (~$500,000).

- Discovered a biomarker that identifies multiple myeloma tumor cell populations susceptible to treatment with an anti-cancer agent (Folotyn/Pralatrexate) –Thesis.- Led a research team of 3 that established an experimental system for detecting cancer-specific immune responses in patients – partnership with a GSK-sponsored cancer vaccine clinical trial.

- Designed an impact/feasibility study targeting attractive IP within 5 therapeutic areas resulting in revision of company’s portfolio strategy.- Analyzed the IP landscape of a licensing target within the antibiotics space.